Embecta Corp. $EMBC Shares Purchased by SummerHaven Investment Management LLC

SummerHaven Investment Management LLC lifted its holdings in Embecta Corp. (NASDAQ:EMBC) by 1.9% in the second quarter, Holdings Channel reports. The firm owned 66,313 shares of the company’s stock after buying an additional 1,268 shares during the period. SummerHaven Investment Management LLC’s holdings in Embecta were worth $643,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in EMBC. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Embecta by 16.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 164,279 shares of the company’s stock worth $3,392,000 after purchasing an additional 23,611 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of Embecta by 4.4% in the 4th quarter. Mackenzie Financial Corp now owns 40,956 shares of the company’s stock worth $846,000 after purchasing an additional 1,743 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Embecta by 2,100.4% in the 1st quarter. GAMMA Investing LLC now owns 19,826 shares of the company’s stock worth $253,000 after purchasing an additional 18,925 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Embecta by 1,261.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 7,391 shares of the company’s stock worth $94,000 after purchasing an additional 6,848 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Embecta by 9.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,004 shares of the company’s stock worth $140,000 after purchasing an additional 907 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EMBC. BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of Embecta in a research report on Friday, September 5th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Mizuho lowered their price target on Embecta from $13.00 to $12.00 and set a “neutral” rating for the company in a research report on Wednesday, July 16th. Finally, Zacks Research raised Embecta from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Embecta currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Embecta Stock Performance

Shares of EMBC opened at $14.00 on Tuesday. The stock has a 50-day moving average of $13.34 and a two-hundred day moving average of $12.00. Embecta Corp. has a one year low of $9.20 and a one year high of $21.48. The stock has a market cap of $818.79 million, a P/E ratio of 9.79, a P/E/G ratio of 0.77 and a beta of 1.12.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Friday, August 8th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.35. The company had revenue of $295.50 million during the quarter, compared to analysts’ expectations of $278.15 million. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.74 EPS. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Analysts predict that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 29th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend was Friday, August 29th. Embecta’s payout ratio is 41.96%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.